New U. S. Rules Could Hike Drug Prices for Some Companies

The government is preparing to slap heavy taxes on foreign drug companies that refuse to cut prices in America. These taxes could double the cost of imported medicines starting this week. The move aims to push drugmakers to build more factories in the U. S. and keep prices low. Big names like Pfizer, AstraZeneca, Eli Lilly, Johnson & Johnson, and Merck have already made deals to avoid these taxes. They’ve promised lower prices or to expand U. S. production. But companies that don’t cooperate could face a 100% tax on their drugs. The rules aren’t final yet, and some medicines might still get exemptions.This isn’t the first time governments have tried to control drug costs. Past efforts have mixed results—some worked, others backfired. Critics say tariffs could hurt global supply chains or even reduce competition. Supporters argue it’s a way to make healthcare more affordable. The debate highlights a bigger question: Who should pay for medicines? Patients, governments, or companies? The answer isn’t simple. Policies like this can have unintended consequences.